Clinical characteristics, treatment and outcome of neonates with SARS-CoV-2 infection
| n/N neonates (%) or median (IQR) | |
| Symptoms | |
| Symptomatic neonates | 26/38 (68) |
| Onset of symptoms, days | 10 (2–19) |
| Fever | 17/34 (50) |
| Gastrointestinal symptoms (diarrhoea and vomiting) | 9/34 (26) |
| Hypoxia | 7/35 (20) |
| Cough | 7/34 (20) |
| Tachycardia | 3/34 (9) |
| Shortening of breathing | 3/34 (9) |
| Rhinorrhoea | 2/34 (6) |
| Seizures | 1/34 (3) |
| Skin lesions | 0/34 (0) |
| Conjunctivitis | 0/34 (0) |
| Therapy | |
| Respiratory management: | |
| Spontaneous breathing (room air) | 27/36 (75) |
| Oxygen supplementation | 3/36 (8) |
| Non-invasive respiratory support | 2/36 (6) |
| Mechanical ventilation | 4/36 (11) |
| Complications* | 2/35 (6) |
| Antibiotics | 7/35 (20) |
| Antiviral drugs | 0/35 (0) |
| Nutrition | |
| Breast feeding | 8/28 (28) |
| Pump milk | 3/28 (11) |
| Formula | 17/28 (61) |
| Outcome | |
| Length of hospital stay, days | 10 (6–14)† |
| Mortality | 0/44 (0) |
*Both neonates had pneumothorax.
†Data available in 24 neonates.